Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 7, 2014
- Accepted in final form August 18, 2014
- First Published December 10, 2014.
Article Versions
- Previous version (December 10, 2014 - 13:01).
- You are viewing the most recent version of this article.
Author Disclosures
- David B. Clifford, MD,
- Florin Vaida, PhD,
- Yu-Ting Kao, MS,
- Donald R. Franklin, BS,
- Scott L. Letendre, MD,
- Ann C. Collier, MD,
- Christina M. Marra, MD,
- Benjamin B. Gelman, MD, PhD,
- Justin C. McArthur, MBBS,
- Susan Morgello, MD,
- David M. Simpson, MD,
- Igor Grant, MD,
- Robert K. Heaton, PhD;
- For the CHARTER Group
- David B. Clifford, MD,
Amgen - PML Adjudication Board 2012 - Biogen Idec/Quintiles - DSMB for progressive MS trial 2011 - BMS - PML Adjudication Committee 2012 - Genentech PML Advisory Board regarding PML 2007 - 2014 Genzyme DSMB for CARE MS Study 2008-2011 Pfizer DMC for MAdCAM study 2011 - Millennium - Chair PML IAC for clinical trials 2009 - 2014 Millennium - ADCETRIS trial adjudication committee member 2012 - Genentech - PML Adjudication Committee (Chair) Etrolizumab trials 2014 - Sanofi - DMSB for MS trial 2014 -
NONE
Sun Pharmaceuticals - Speaker Honorarium - Symposium in Pune India (2013) Emory University - Speaker Honorarium for grand rounds University of Kansas - Speaker Honorarium for grand rounds
NONE
NONE
NONE
NONE
Millennium Consulting regarding PML 2007-2014 Genzyme consultant 2009-2013 Biogen Idec scientific advisor regarding PML 2005-2014 IAS-USA speaker honorarium 2012 CMSC/ACTRIMS speaker honorarium 2012 ECTRIMS spearker honorarium 2012 Drinker, Biddle, Reath - Chair Scientific Advisory Committee of PML Consortium 2010 - Cytheris - PML trial design, FDA 2012 - 2013 Novartis - Case review consult for PML diagnosis - 2014
NONE
NONE
NONE
Lilly (DIAN - TU) 2013 - Roche (DIAN - TU) 2013 -
NIH UO1 A169495 AIDS Clinical Trials Unit 2013-2020 NIH U10 NS077384 NeuroNEXT Trials Unit 2011- 2018 NIMH 22005 CHARTER Project (Washington U Site PI) 2007 - 2015 NIH R01 NR012907 (NINR,Ances - PI), Co-investigator, 2010- 2015 NIH R01 NR012907 (NINR, Ances - PI), Co-investigator, 2011-2016 DIAN TTU 12-243040 (Alzheimer Association, Bateman PI), Co-investigator, 2012-2016.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Arnold Todoro & Welch (legal consultation)2012 - Rainey, Kizer, Reviere, Bell (case review 2013 Silver and Deboskey PC (legal case review) 2013 Drinker Biddle and Reath LLC (PML Consortium Scientific Advisory Board) 2012 -
- Florin Vaida, PhD,
NONE
NONE
NONE
Research Methodology Section Editor for the Californian Journal of Health Promotion Editor, ISRN-AIDS Frontiers in Genetics, Research Editor
NONE
NONE
NONE
(1) Statistical Consultant for Washington University in St Louis.
NONE
NONE
NONE
NONE
NIH MH22005HIV, Investigator, 2006-2011 NIH MH083552, Investigator, 2008-2013 NIH MH62512, Investigator, 2007-2011 NIH AI074521, Investigator, 2007-2012 NIH MH085608, Investigator, 2009-2013 NIH MH58076, Investigator, 2008-2011
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yu-Ting Kao, MS,
NONE
NONE
NONE
NONE
NONE
NONE
(1) Eli Lilly and company, Sr. Statistician-computation, since 8/4/2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Donald R. Franklin, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIMH N01 MH22005; HHSN271201000036C; HHSN271201000030C, Center Manager 2006-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Scott L. Letendre, MD,
NONE
NONE
(1) ViiV Healthcare, 2013 (2) Abbvie, 2013
NONE
NONE
NONE
NONE
Merck & Co., Inc., 2012
NONE
NONE
NONE
(1) GlaxoSmithKline, Paid to the University of California (2) Merck & Co., Inc., Paid to the University of California (3) Abbvie, Paid to the University of California
(1) NIH, U01 MH083506, consultant, 2012 (2) NIH, R01 MH58076, co-investigator, 2012 (3) NIH, P50 DA26306, co-investigator, 2012, 2013 (4) NIH, R01 MH73433, co-investigator, 2012 (5) NIH, N01 MH22005, co-investigator, 2012, 2013 (6) NIH, P30 MH62512, co-investigator, 2012, 2013 (7) NIH, R01 MH78748, co-investigator, 2012 (8) NIH, R21 MH85610, principal investigator, 2012 (9) NIH, R01, MH92225, principal investigator, 2012, 2013 (10) NIH, K24, MH097673, principal investigator, 2013
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ann C. Collier, MD,
(1) Data and Safety Monitoring Board for Merck & Co.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Schering-Plough - past research contract (2) Merck & Co.- past research contract (3) Roche Molecular Systems - past research contract
(1) NIH/NIMH, N01 MH22005, Collier Co-PI on Subcontract, 3/12/03-8/31/15 (2) NIH/NIAID, UM1 AI 069481, Collier PI on Subcontract, 12/10/13 ? 11/30/2020 (3) NIH/NIAID, UM1 AI 069434, Collier, PI, 1/1/07-5/30/14 (4) NIH/NIAID, P01 AI 057005, Collier, Core PI, 10/01/03- 6/30/15 (5)NIH/NIMH, R01 NS082120, Collier Co-Investigator, 7/1/13-3/31/18 (6)NIH/NIAID, R01 AI090783, Collier, Co-Investigator, 6/1/10-5/31/14 (7)NIH/NIAID, UM1 AI068636, Co-Investigator, 6/1/13- 1/31/14 (8)NIH/NINDS, RC1NS068904, Collier, Co-Investigator, 9/22/09-8/31/12 (9)NIH/NIAID, AI069918, Co-Investigator of Subcontract, 4/1/06-6/30/16 (10)Social and Scientific Systems (pass through funds from NIH), CRB-SSS-5-11-000930/CRB-DCR01-5-09-00291, Collier, PI on contract, 2/2/11-3/31/13 (11)Social and Scientific Systems, pass through funds from NIH, BRS-ACURE-S-11-00046-001329, Collier, PI of contract, 6/1/10-5/31/12 Stock/Stock Options, Medical Equipment & Materials: (1) Abbott Laboratories, former stock owner, sold stock 8/23/12 (2) Bristol-Myers-Squibb, former stock owner, sold stock 8/23/12 (3) Johnson and Johnson, former stock owner, sold stock 8/23/12 (4) Pfizer, former stock owner, sold stock 8/23/12
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christina M. Marra, MD,
NONE
NONE
NONE
NONE
NONE
I receive royalties from UpToDate for an article that I wrote on neurosyphilis. I receive royalties for a text entitled Infections of the Central Nervous System 4d ed, published by LWW in 2014.
NONE
NONE
NONE
NONE
NONE
NONE
1) NIH, NS34235, PI, 1996-2014; NIH, NS082120, PI, 2013-14; NIH, MH22005, Co-investigator, 2003-2014; NIH, AI094126, Co-investigator, 2012-2014; NIH, AI069434, Site Neurologist, 2007-2013; NIH, AI094122, Co-investigator, 2011-2013; NIH, NS32228, Co-investigator, 1997-2011; NIH, AI068636, PI on subcontract, 2011-2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Benjamin B. Gelman, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) National Institute of Mental Health, U01MH083507, 2008- 2010. 2) National Institute of Mental Health, R01MH079886, 2006- 2010. 3) National Institute of Mental Health, N01MH022005, 2003- 2010.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Justin C. McArthur, MBBS,
Relevare, scientific advisory board. 2006 - present. Stock options
NONE
NONE
NONE
Murphy JC, Szczepanowski RP, Schneider W, Meyer RA, McArthur JC, Polydefkis M. Device for thermal stimulation of small neural fibers. World Intellectual Property Organization,International Publication Number WO 03/040672 A2, 15 May 2003. Murinson BB, McArthur JC. Medical Device for Treatment of Ulnar Neuropathy. UlnarGuard ? (JHU Ref: 4545) Nath A, Hoke A, McArthurJC. Immunophilin ligand treatment of antiretroviral toxic neuropathy (Provisional application number 60/466,650)
NONE
NONE
NONE
NONE
NONE
NONE
Biogen Idec 2009- (PI on clinical trial) Pfizer 2010 (PI on clinical trial)
NIH research funding 1986 - present
NONE
Foundation for Peripheral Neuropathy research grant 2008- present
NONE
NONE
NONE
NONE
NONE
NONE
- Susan Morgello, MD,
Not-for-profit; Advisory Board member, Temple University Comprehensive NeuroAIDS Center (CNAC)
NONE
NONE
Journal of Neurovirology, editorial board, 2001 to present, no compensation received
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH: R24MH59724, U01MH083501, U24MH100931, PI, 1998-present R25MH080663, PI, 2007-present N01MH22005, Subsite PI, 2001-present R01DA037611, Subsite PI, 2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David M. Simpson, MD,
Scientific advisory board: Allergan,Merz, Astellas, Acorda
NONE
Speaker honoraria: Allergan
AIDS Patient Care (2008-current)
NONE
Neuropathic Pain: Mechanisms, Diagonosis and Management; Oxford; 2012
Icahn School of Medicine at Mount Sinai
Allergan, Acorda, Astellas
Allergan
NONE
NONE
Allergan, Merz, Ipsen, US Worldmeds, Astellas, Viromed, CSL Behring
NINDS: R01-NS328-05-co-inv; R24 MH59724-co-inv;R01-NS- 41198-co-inv; NIMH-00-AI-0005-co-PI
NONE
Peripheral Neuropathy Foundation
NONE
NONE
NONE
NONE
NONE
Proctor and Gamble: 2012-2014
- Igor Grant, MD,
NONE
NONE
Abbott Pharmaceuticals speaker fee AbbVie speaker fee
(1)Journal of the International Neuropsychological Society, Associate Editor, 2002-2004, (2) Journal of Neurovirology, Associate Editor, 2002-present
NONE
NONE
NONE
NONE
Abbott Pharmaceuticals
NONE
NONE
NONE
(1) NIDA, DA26306, PI, 2009-present, (2) NIMH, MH83506, PI, 2002-present, (3) NIMH, HHSN271201000036C, PI, 2010-present, (4) NIMH, HHSN271201000030C, PI, 2010-present, (5) NIMH, MH094159, Co-I, 2011-present (6) NIMH, MH62512, Co-I, 2011-present, (7) NIMH, MH78748, Co-I, 2007-2013, (8) NIMH, MH83552, Co-I, 2008-2013, (9) NIA, AG15301, PI, 2002-2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Robert K. Heaton, PhD;
(1) NINCDS, advisor, 2007-2010
NONE
NONE
(1) Journal of the International Neuropsychological Society, editorial board, 2000-present, (2) Journal of Clinical and Experimental Neuropsychology, editorial board, 2000-present, (3) The Clinical Neuropsychologist, editorial board, 2000-present
NONE
(1) Revised Comprehensive Norms for and Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults, Psychological Assessment Resources, Inc., 1991-present (2) Revised Comprehensive Norms for and Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults Scoring Program, Psychological Assessment Resources, Inc., 1994-present (3) Wisconsin Card Sorting Test Manual-Revised and Expanded, Psychological Assessment Resources, Inc., 1991-present
NONE
NONE
NONE
NONE
NONE
NONE
(1)NIH P30 MH62512, Co-Investigator, 2006-2010, (2)NIH P50 DA26306, Co-Investigator, 2009-2010, (3) NIH P01 DA12065, Co-Investigator, 2005-2010, (4) NIH R01 MH60720, Co-Investigator, 2006-2010, (5) NIH R01 MH73433, Principal Investigator, 2005-2010, (6) NIH N01 MH22005, Co-Investigator, 2002-2010, (7) NIH R01 MH58076, Co-Investigator, 2006-2010, (8) NIH R01 MH78748,Co-Investigator, 2007-2010, (9) NIH R01 MH78737, Co-Investigator, 2007-2010, (10) NIH U01 MH83506, Co-Investigator, 2008-2010, (11) NIH R01 MH83552,Co-Investigator, 2008-2010, (12) NIH R01 MH81861, Co-Investigator, 2008-2010, (13) NIH P30MH062512-11, Principal Investigator, 2011-2016.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- For the CHARTER Group
- From Washington University (D.B.C.), St. Louis, MO; University of California (F.V., Y.-T.K., D.R.F., S.L.L., I.G., R.K.H.), San Diego; University of Washington (A.C.C., C.M.M.), Seattle; University of Texas at Galveston (B.B.G.); Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
- Correspondence to Dr. Clifford: cliffordd{at}wustl.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamineM. Cherner, S. Letendre, R. K. Heaton et al.Neurology, April 07, 2005 -
Article
Global prevalence and burden of HIV-associated neurocognitive disorderA meta-analysisYunhe Wang, Moxuan Liu, Qingdong Lu et al.Neurology, September 04, 2020 -
Brief Communications
Hepatitis C virus infection and neurocognitive functionM. Soogoor, H. S. Lynn, S. M. Donfield et al.Neurology, October 23, 2006 -
Article
Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected personsNancy F. Crum-Cianflone, David J. Moore, Scott Letendre et al.Neurology, January 09, 2013